Pharmacotherapy for stress urinary incontinence: Present and future options

Drugs

Volumn 64, Issue 14, 2004, Pages 1503-1516

  Zinner, Norman R ^a   Koke, Stephanie C ^b   Viktrup, Lars ^b  

^a Western Clinical ResearchInc   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BULKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLENBUTEROL; DULOXETINE; EPHEDRINE; ESTROGEN; IMIPRAMINE; METHOXAMINE; MIDODRINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NOREPHEDRINE; NORFENEFRINE; OXYBUTYNIN; PHENYLPROPANOLAMINE; PROGESTERONE; PROPRANOLOL DERIVATIVE; PSEUDOEPHEDRINE; SEROTONIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BLADDER SPHINCTER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLD TOLERANCE; CONSTIPATION; COST BENEFIT ANALYSIS; DISORIENTATION; DROWSINESS; FALLING; HEADACHE; HEALTH CARE; HEART FAILURE; HEART PALPITATION; HEART RHYTHM; HUMAN; HYPERTENSION; META ANALYSIS; MUSCLE CONTRACTILITY; MUSCLE TRAINING; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PELVIS FLOOR; PHYSICAL ACTIVITY; QUALITY OF LIFE; REFLEX; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEDATION; SIDE EFFECT; SLEEP DISORDER; SPHINCTER; STRESS INCONTINENCE; SURGICAL TECHNIQUE; TACHYCARDIA; TREMOR; URETHRA FUNCTION; URINE INCONTINENCE; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

ANIMALIA;

EID: 3242767720     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464140-00001     Document Type: Review

References (105)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002; 187 (1): 116-26
2. Hunskaar S, Arnold EP, Burgio K, et al. Epidemiology and natural history of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11 (5): 301-19
3. Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT Study. J Clin Epidemiol 2000; 53 (11): 1150-7
4. Koelbl H, Mostwin J, Boiteux JP, et al. Pathophysiology. In: Abrams P, Khoury S, Wein A, editors. Incontinence. Plymouth: Health Publication Ltd, 2002: 205-41
5. Viktrup L. The risk of lower urinary tract symptoms five years after the first delivery. Neurourol Urodyn 2002; 21 (1): 2-29
6. Bump RC, Norton PA. Epidemiology and natural history of pelvic floor dysfunction. Obstet Gynecol Clin North Am 1988; 25: 723-46
7. Viktrup L. Female stress and urge incontinence in family practice: insight into the lower urinary tract. Int J Clin Pract 2002; 56 (9): 694-700
8. Fultz NH, Herzog AR. Self-reported social and emotional impact of urinary incontinence. J Am Geriatr Soc 2001; 49 (7): 892-9
9. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48 (7): 721-5
10. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26 (5): 367-74
11. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001; 98 (3): 398-406
12. Berglund A, Fugl-Meyer K. Some sexological characteristics of stress incontinent women. Scand J Urol Nephrol 1996; 30 (3): 207-12
13. Fultz NH, Burgio K, Diokno AC, et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003; 189 (5): 1275-82
14. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 1998; 51 (3): 355-61
15. Wall L, Norton PA, DeLancey JO. Absorbent products and catheters. Baltimore (MD): Williams and Wilkins, 1993
16. Kinchen KS, Bump RC, Gohier J. Prevalence and frequency of stress urinary incontinence among community-dwelling women [abstract]. Eur Urol Suppl 2002; 1 (1): 85
17. Dugan E, Roberts CP, Cohen SJ, et al. Why older community-dwelling adults do not discuss urinary incontinence with their primary care physicians. J Am Geriatr Soc 2001; 49 (4): 462-5
18. Cheater FM, Castleden CM. Epidemiology and classification of urinary incontinence. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14 (2): 183-205
19. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998; 46 (4): 473-80
20. Cammu H, Van Nylen M, Amy JJ. A 10-year follow-up after Kegel pelvic floor muscle exercises for genuine stress incontinence. BJU Int 2000; 85 (6): 655-8
21. Bo K. Pelvic floor muscle exercise for the treatment of genuine stress incontinence: an exercise physiology perspective. Int Urogynecol J 1995; 6: 282-91
22. Morkved S, Bo K. Effect of postpartum pelvic floor muscle training in prevention and treatment of urinary incontinence: a one-year follow up. Br J Obstet Gynecol 2000; 107 (8): 1022-8
23. Ashworth PD, Hagan MP. Some social consequences of noncompliance with pelvic floor exercises. Physiotherapy 1993; 79: 465-71
24. Burns B, Pranikoff K, Nochajski T, et al. A comparison of effectiveness of biofeedback and pelvic muscle exercise treatment of stress incontinence in older community-dwelling women. J Gerontol Med Sci 1993; 48: M167-74
25. Lapitan MC, Cody DJ, Grant AM. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev 2003; (1): CD002912
26. Bezerra CA, Bruschini H. Suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2000; (3): CD001754. Update in: Cochrane Database Syst Rev 2001; (3): CD001754
27. Bezerra CA, Bruschini H. Suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2000; (3): CD001754. Update in: Cochrane Database Syst Rev 2001; (3): CD001754
28. Nilsson CG, Kuuva N, Falconer C, et al. Long-term results of the tension-free vaginal tape (TVT) for surgical treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12 Suppl. 2: S5-8
29. Hilton P. Trials of surgery for stress incontinence: thoughts on the 'Humpty Dumpty principle'. Br J Obstet Gynecol 2002; 109 (10): 1081-8
30. Black NA, Downs S. The effectiveness of surgery for stress incontinence in women: a systematic review. Br J Urol 1996; 78: 497-510
31. Herschorn S. Current status of injectable agents for female stress urinary incontinence. Can J Urol 2001; 8 (3): 1281-9
32. Burkhart KS. Urinary incontinence in women: assessment and management in the primary care setting. Nurse Pract Forum 2000; 11 (4): 192-204
33. Andersson K-E, Appell R, Awad S, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Khoury S, Wein A, editors. Incontinence. Plymouth: Health Publications Ltd, 2002: 481-511
34. Abrams P, Khoury S, Wein A, editors. Incontinence (2nd International Consultation on Incontinence, WHO). Plymouth: Health Publications Ltd, 2002
35. Versi E, Cardozo L. Estrogens and the lower urinary tract function. London: Blackwell Scientific, 1988
36. Hodgson BJ, Dumas S, Bolling DR, et al. Effect of estrogen on sensitivity of rabbit bladder and urethra to phenylephrine. Invest Urol 1978; 16 (1): 67-9
37. Larsson B, Andersson K, Batra S, et al. Effects of estradiol on norepinephrine-induced contraction, alpha adrenoceptor number and norepinephrine content in the female rabbit urethra. J Pharmacol Exp Ther 1984; 229: 557-63
38. Bump RC, Friedman CI. Intraluminal urethral pressure measurements in the female baboon: effects of hormonal manipulation. J Urol 1986; 136 (2): 508-11
39. Hextall A. Oestrogens and lower urinary tract function. Maturitas 2000; 36 (2): 83-92
40. Fantl JA, Bump RC, Robinson D, et al. Efficacy of estrogen supplementation in the treatment of urinary incontinence: the Continence Program for Women Research Group. Obstet Gynecol 1996; 88 (5): 745-9
41. Jackson DA, Shepherd A, Abrams P. The effect of oestradiol on objective urinary leakage in postmenopausal stress incontinence: a double blind placebo control trial [abstract]. Neurourol Urodyn 1996; 15: 322
42. Blakeman PJ, Hilton P, Bulmer JN. Cellular proliferation in the female lower urinary tract with reference to oestrogen status. BJOG 2001; 108 (8): 813-6
43. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994; 83 (1): 12-8
44. Sultana C, Walters M. Estrogen and urinary incontinence in women. Maturitas 1990; 20: 129-38
45. Al-Badr A, Ross S, Soroka D, et al. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? J Obstet Gynaecol Can 2003; 25 (7): 567-74
46. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2003 (2): CD001405
47. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97 (1): 116-20
48. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285 (11): 1460-5
49. Porch J, Lee IM, Cook NR, et al. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002; 13 (9): 847-54
50. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289 (24): 3243-53
51. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362 (9382): 419-27
52. Goode PS, Burgio KL. Pharmacologic treatment of lower urinary tract dysfunction in geriatric patients. Am J Med Sci 1997; 314 (4): 262-7
53. Brune ME, O'Neill AB, Gauvin DM, et al. Comparison of alpha 1-adrenoceptor agonists in canine urethral pressure profilometry and abdominal leak point pressure models. J Urol 2001; 166 (4): 1555-9
54. Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Urology 1975; 5 (5): 624-5
55. Awad SA, Downie JW, Kiruluta HG. Alpha-adrenergic agents in urinary disorders of the proximal urethra: part I. Sphincteric incontinence. Br J Urol 1978; 50 (5): 332-5
56. Ek A, Andersson KE, Gullberg B, et al. The effects of long-term treatment with norephedrine on stress incontinence and urethral closure pressure profile. Scand J Urol Nephrol 1978; 12 (2): 105-10
57. Collste L, Lindskog M. Phenylpropanolamine in treatment of female stress urinary incontinence: double-blind placebo controlled study in 24 patients. Urology 1987; 30 (4): 398-403
58. Siltberg H, Larsson G, Hallen B, et al. Validation of cough-induced leak point pressure measurement in the evaluation of pharmacological treatment of stress incontinence. Neurourol Urodyn 1999; 18 (6): 591-602
59. Beisland HO, Fossberg E, Moer A, et al. Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination: a urodynamic and clinical evaluation. Urol Int 1984; 39 (4): 211-6
60. Hilton P, Tweddel A, Mayne C. Oral and intravaginal estrogens alone and in combination with alpha adrenergic stimulation in genuine stress incontinence. Int Urogynecol J 1990; 12: 80-6
61. Fleming G. The FDA, regulation, and the risk of stroke. N Engl J Med 2000; 343: 1886-7
62. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343 (25): 1826-32
63. Weil EH, Eerdmans PH, Dijkman GA, et al. Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9 (3): 145-50
64. Radley SC, Chapple CR, Bryan NP, et al. Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind cross-over study. Neurourol Urodyn 2001; 20 (1): 43-52
65. Gatti JM, Perez-Brayfield M, Kirsch AJ, et al. Acute urinary retention in children. J Urol 2001; 165 (3): 918-21
66. Andersson KE. Neurotransmission and drug effects in urethral smooth muscle. Scand J Urol Nephrol Suppl 2001; (207): 26-34
67. Nasu K, Moriyama N, Fukasawa R, et al. Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 1998; 123 (7): 1289-93
68. Ishiko O, Ushiroyama T, Saji F, et al. Beta (2)-adrenergic agonists and pelvic floor exercises for female stress incontinence. Int J Gynaecol Obstet 2000; 71 (1): 39-44
69. Yasuda K, Kawabe K, Takimoto K. A double-blind clinical trial of a β2-adrenergic agonist in stress incontinence [abstract]. Int Urogynecol J 1993; 4: 146
70. Noguchi M, Eguchi Y, Ichiki J, et al. Therapeutic efficacy of clenbuterol for urinary incontinence after radical prostatectomy. Int J Urol 1997; 4 (5): 480-3
71. Gleason DM, Reilly RJ, Bottaccini MR, et al. The urethral continence zone and its relation to stress incontinence. J Urol 1974; 112 (1): 81-8
72. Kaisary AV. Beta adrenoceptor blockade in the treatment of female urinary stress incontinence. J Urol (Paris) 1984; 90 (5): 351-3
73. Rovner ES, Wein A. Drug treatment of voiding dysfunction. 1st ed. London: Isis Medical Media, 2001
74. Gilja I, Radej M, Kovacic M, et al. Conservative treatment of female stress incontinence with imipramine. J Urol 1984; 132 (5): 909-11
75. Lin HH, Sheu BC, Lo MC, et al. Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol 1999; 106 (10): 1089-92
76. Woodman PJ, Misko CA, Fischer JR. The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12 (5): 312-5
77. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol 1997; 17 Suppl. 1: 2S-18S
78. Khullar V, Digesu A, Chaliha C, et al. Mixed incontinence: how should it be treated? Neurourol Urodyn 2002; 21 (4): 378-9
79. Espey MJ, Du HJ, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 1998; 798 (1-2): 101-8
80. Thor KB, Hisamitsu T, de Groat WC. Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N- dimethyltryptamine. Brain Res Dev Brain Res 1990; 54 (1): 35-42
81. Danuser H, Thor KB. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br J Pharmacol 1996; 118 (1): 150-4
82. Gajewski J, Downie JW, Awad SA. Experimental evidence for a central nervous system site of action in the effect of alpha-adrenergic blockers on the external urinary sphincter. J Urol 1984; 132 (2): 403-9
83. Espey MJ, Downie JW, Fine A. Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 1992; 221 (1): 167-70
84. Bae JH, Moon DG, Lee JG. The effects of a selective noradrenaline reuptake inhibitor on the urethra: an in vitro and in vivo study. BJU Int 2001; 88 (7): 771-5
85. Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11 (6): 386-8
86. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25 (6): 871-80
87. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187 (1): 40-8
88. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003; 170: 1259-63
89. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine vs placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004; 111: 249-57
90. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 106-32
91. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993; 8 (1): 23-33
92. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995; 274 (2): 1014-24
93. Katofiasc MA, Nissen J, Audia JE, et al. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 2002; 71 (11): 1227-36
94. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000; 40 (2): 161-7
95. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73 (3): 170-7
96. diVirgilio S, Gonzales C, Knadler M, et al. Effect of duloxetine (DU) on CYP1A2-mediated drug metabolism and the pharmacokinetics (PK) of theophylline (THEO) [abstract]. Clin Pharmacol Ther 2002; 71 (2): 63
97. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology 2003; 28 (9): 1685-93
98. Sathirakul K, Teng L, Yeo K, et al. Impact of gastric pH and the presence of activated charcoal on the absorption of duloxetine [abstract]. Clin Pharmacol Ther 2002; 71 (2): 18
99. Bump R, Hooper C, Koke S, et al. Worldwide efficacy of duloxetine after 12 weeks and 1 year in women with stress urinary oncontinemce (SUI): a 4-study meta-analysis [abstract no. 337]. 33rd Annual International Continence Society Meeting; 2003 Oct 5-9; Florence
100. Dubeau CE, Khullar V. Drug impact on the SUI component of mixed incontinence: is it all placebo effect? [abstract]. American Urogynecologic Society Meeting; 2002 Oct 16-19; San Francisco
101. Ramsay IN, Thou M. A randomised, double-blind, placebo controlled trial of pelvic floor exercises in the treatment of genuine stress incontinence. Neurourol Urodyn 1990; 9: 398-9
102. Bailar III JC. The powerful placebo and the wizard of Oz. N Engl J Med 2001; 344: 1630-2
103. Mallinckrodt C, Goldstein DJ, Detke MJ, et al. Duloxetine: a new treatment for the emotional and physical symptoms of depression. Primary Care Companion J Clin Psych 2003; 5: 19-28
104. Raskin J, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in the long-term treatment of major depressive disorder [poster]. Presented at the US Psychiatric and Mental Health 15th Annual Congress; 2002 Oct 28-31; Las Vegas
105. Brannan S, Detke MJ, Wang F, et al. Comparison of sexual functioning in patients receiving duloxetine or paroxetine: acute- and long-term data [poster]. Presented at the American Psychiatric Association 156th Annual Meeting; 2003 May 17-22; San Francisco